ADH and AVP Deficiency: Understanding the Relationship
ADH (antidiuretic hormone) and AVP (arginine vasopressin) are the same hormone—they are simply different names for the identical molecule. Therefore, AVP deficiency IS ADH deficiency, and the terms are completely interchangeable 1, 2.
Key Terminology Update
The nomenclature was officially changed in 2022 to improve clarity and avoid confusion with diabetes mellitus 2:
- "Central diabetes insipidus" is now called "AVP deficiency"
- "Nephrogenic diabetes insipidus" is now called "AVP resistance"
Pathophysiology of AVP Deficiency
AVP/ADH is synthesized in the hypothalamus and released from the posterior pituitary 1. When AVP is deficient, the kidney loses its ability to concentrate urine, leading to:
- Polyuria (excessive urination)
- Polydipsia (excessive thirst)
- Risk of hypertonic dehydration and hypernatremia 1
The hormone normally acts on V2 receptors in the kidney collecting ducts, stimulating aquaporin-2 (AQP2) water channels to promote water reabsorption 3. Without adequate AVP, this mechanism fails, resulting in inappropriately diluted urine even when the body needs to conserve water 1.
Clinical Presentation
In AVP deficiency, the diagnostic hallmark is:
- Serum osmolality usually >300 mOsm/kg H₂O (due to hypernatremia)
- Urine osmolality <200 mOsm/kg H₂O (inappropriately diluted)
- Urine osmolality remains less than plasma osmolality 1
In infants, the mean age at diagnosis is approximately 4 months, presenting with polyuria, failure to thrive, and dehydration 1. Infants are particularly vulnerable as they cannot access fluids independently.
Treatment: DDAVP (Desmopressin)
DDAVP, a synthetic analogue of ADH/AVP, is the mainstay of treatment for AVP deficiency 4. DDAVP acts primarily on V2 receptors with minimal vasopressor activity 4.
Administration Routes and Dosing
DDAVP can be administered via multiple routes 4:
- Oral tablets: 100-400 μg (absorption ~1%)
- Intranasal spray: 10 μg per spray (absorption ~6%)
- Sublingual melts: dose ratio to intranasal is 1:24
- Subcutaneous injection
Use the lowest effective dose that allows adequate nighttime rest and minimal disruption of daytime activities 4. Treatment must be individualized based on work schedules, travel, and medication response variability 4.
Critical Safety Considerations
The primary adverse effect is dilutional hyponatremia, which can be life-threatening 4. To prevent this:
- Implement the "desmopressin escape method": Patients must experience a phase of polyuria at least weekly where the medication effect has clearly worn off 4
- Monitor serum sodium closely, especially in elderly patients who have increased renal sensitivity 4
- Educate patients about overdosing risks 4
- Check electrolytes during intercurrent illnesses that affect hydration or drug absorption 5
Special Populations
In adipsic AVP deficiency (damaged thirst mechanism from hypothalamic pathology), there is high risk of both hypernatremia and hyponatremia because patients cannot adjust fluid intake appropriately 4. These patients require:
- Careful DDAVP and fluid intake titration
- Frequent weighing
- Close serum sodium monitoring 4
Post-pituitary surgery: Attempt to discontinue DDAVP during the weeks to months after surgery to determine if posterior pituitary function has recovered 4. AVP deficiency occurs in approximately 26% of children after transsphenoidal pituitary surgery 6.
Common Pitfalls to Avoid
Water intoxication: While rare (only 11 reported cases with DDAVP), it can cause seizures from hyponatremia 5. Most cases involved complicating factors like excessive water drinking or overdose.
Failure to recognize the triphasic pattern after pituitary surgery: transient AVP deficiency → inappropriate antidiuresis (SIADH) → permanent AVP deficiency 6
Confusing AVP deficiency with AVP resistance (nephrogenic DI): In AVP resistance, the kidney is insensitive to AVP despite normal or elevated hormone levels 1. DDAVP will not be effective in true AVP resistance.
Not monitoring for endogenous ADH suppression: Concern about depression of endogenous ADH with extended DDAVP use appears unwarranted—children using DDAVP for up to 1 year maintain ability to concentrate urine appropriately 5.
Emergency Preparedness
All patients with AVP deficiency should wear an emergency bracelet or necklace to inform clinicians of their condition if incapacitated 4.